

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 1E




FIG. 1F




FIG. 1G




FIG. 1H




FIG. 11




FIG. 2A




FIG. 2B

FIG. 2C

FIG. 2D




FIG. 3A




FIG. 3B



FIG. 3C



Q79-GFP

FIG. 3D



FIG. 3E




FIG. 3F



Daunomycin

Chrysamine G

Rolitetracycline

Congo Red

FIG. 4A




FIG. 4B




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D




FIG. 5E




FIG. 5F




FIG. 5G




FIG. 5H





FIG. 5I



Q79-GFP / Congo Red

FIG. 6A





FIG. 6B






FIG. 6D




FIG. 6E






FIG. 7A

FIG. 7B




FIG. 7C

FIG. 8A




FIG. 8B




FIG. 8C




FIG. 9




FIG.10A




FIG.10B

Fasting (6 hrs) glucose levels	
Wt	PBS-IP 152 mg/dl \pm 27
Wt	Congo Red-IP 216 mg/dl \pm 60 p>0.05
HD1 Tg	PBS-IP 398 mg/dl \pm 98 p<0.01**
HD1 Tg	Congo Red-IP 178 mg/dl \pm 46 p>0.05, *p<0.05

FIG.10C




FIG. 10D




FIG. 10F





FIG. 10G



Stride: $\frac{\text{Tg-HD1 R62-IP inj}}{\text{vehicle Congo red}}$
 Stride: -46% -17% $p < 0.01$

FIG. 10E

FIG. 11A



Tg-HD1 R62
FIG. 11B 12.5 postnatal weeks




FIG. 11D



FIG. 11C




FIG. 11E




FIG. 11F




FIG. 12A %ATP levels compound treated (Q79/GFP)/ (GFP)




FIG. 12B % luciferase activity Q79 (compound/vehicle)




FIG. 13A




FIG. 13B




FIG. 14A





FIG. 14B







FIG. 14C

Q79 compound library

PQIC



PQIC-1






PQIC-1

PQIC : 1 = H
PQIC-1 : 1 = NO_2-

CBL#243678
CBL#243676

FIG. 14D



PQID : 1=Cl, 2=H, 3=H CBL#163012
 PQIM : 1=H, 2=NO₂, 3=H CBL#162753
 PQID-1 : 1=Br, 2=H, 3=NO₂ CBL#162728
 PQID-2 : 3=Br, 2=H, 3=H CBL#162759







FIG. 14E

PQIF





PQIF

PQIF : 1= NO_2 CBL#100707
PQIF-1 : 1=Br CBL#122267
PQIF-2 : 1= O_2 CBL#136395


FIG. 14F

PQIG



PQIG

PQIG 1=H, 2= H, 3= CH₃, 4= CH₃, 5= H CBL#104413



PQIG-1 : 3, 4= 1,2,5,6=H CBL#104234

PQIG-2 : 1, 2=CH₃, 3,4= 5,6=H CBL#116574

PQIG-3 : 3,4= 1,2=H
5,6=CH₃ CBL#105109

PQIG-4 : 3,4= 1,2,5,6=H CBL#105560

PQIG-5 : 3,4= 1,2,5,6=H CBL#116580

PQIG-6 : 3,4= 1,2,5,6=H CBL#153040

FIG. 14G




FIG. 14J




FIG. 14H




FIG. 14K




FIG. 14I




FIG. 14L




FIG. 15A

#1: CNC-43921




FIG. 15B

#2: CNC-43267




FIG. 15C FIG. 15D

FIG. 15C
CNC - 49867




FIG. 15D
4 CNC - 49867




FIG. 15E

#5: CNC-54580




FIG. 15F

#6: CNC-42175




FIG. 15G

#7: CNC-42379




FIG. 15H

#8: CNC-46308




FIG. 15I

#9: CNC-46793




FIG. 15J

#10: CNC-49373




FIG. 15K

#1: CNC-57277




FIG. 15L

#1: CNC-556240




FIG. 15M

#2: CNC-526900




FIG. 15N

#3: CNC-431893




FIG. 15O

#4: CNC-523618




FIG. 15P

#5: CNC-555148





FIG. 15Q

#6: CNC-521484



© 2023 J. Wiley & Sons, Inc.

FIG. 15R

#7: CNC-543738




FIG. 15S

#8: CNC-529717




FIG. 16A

#1: CNC-289284




FIG. 16B

#2: CNC-1069242




FIG. 16C

#3: CNC-287671




FIG. 16D

#4: CNC-287227




FIG. 16E

#5: CNC-300273 and CNC-1268328




FIG. 16F

#7: CNC-1308309




FIG. 16G

#8: CNC-1069226




FIG. 16H

#9: CNC-290524




FIG. 16I

#10: CNC-609843




FIG. 16J

#11: CNC-1059876




FIG. 16K

#12: CNC-300196




FIG. 16L

#13: CNC-287437




FIG. 16M

#14: CNC-301181

#15: CNC-628178

#16: CNC-1292419




FIG. 17A




FIG. 17C




FIG. 17B




FIG. 17D




FIG. 17F




FIG. 17E




FIG. 17G




FIG. 17H




FIG. 17I






FIG. 17J



appx. IC₅₀ = 15µM

appx. IC₅₀ = 10µM

appx. IC₅₀ = 8µM

FIG. 17K




FIG. 17L




FIG. 17N




FIG. 17M




FIG. 17O




FIG. 18A





FIG. 18B



6- α -Methylprednisolone 21-hemisuccinate

FIG. 18C






FIG. 18D




azathioprine

FIG. 18E




D-cycloserine

FIG. 18F




N-Vanillylnonamide

FIG. 18G




bromocriptine mesylate

FIG. 18H




Haloperidol

FIG. 18I




Nabumetone

FIG. 18J




Primidone

FIG. 18K




Phenazopyridine

FIG. 18L




N-Vanillylidene

FIG. 18M



8-methyl-N-vanillyl-6-nonenamide

FIG. 18N



R-(*-*)-deprenyl hydrochloride




FIG. 180

FIG. 19

